Now showing items 1-5 of 5

    • Nintedanib in ovarian cancer. 

      Khalique, S; Banerjee, S (2017-09)
      INTRODUCTION: Advanced ovarian cancer remains an unmet clinical need. Angiogenesis is considered a therapeutic target in ovarian cancer, with bevacizumab, a monoclonal antibody against VEGF, being the first drug to show a ...
    • Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers. 

      Khalique, S; Naidoo, K; Attygalle, AD; Kriplani, D; Daley, F; Lowe, A; Campbell, J; Jones, T; Hubank, M; Fenwick, K; Matthews, N; Rust, AG; Lord, CJ; Banerjee, S; Natrajan, R (2018-07)
      ARID1A is a tumour suppressor gene that is frequently mutated in clear cell and endometrioid carcinomas of the ovary and endometrium and is an important clinical biomarker for novel treatment approaches for patients with ...
    • The spatio-temporal evolution of lymph node spread in early breast cancer 

      Barry, P; Vatsiou, A; Spiteri Sagastume, I; Nichol, D; Cresswell, G; Acar, A; Trahearn, N; Hrebien, S; Garcia-Murillas, I; Chkhaidze, K; Ermini, L; Cottom, H; Zabaglo, L; Koelble, K; Khalique, S; Rusby, J; Muscara, F; Dowsett, M; Maley, C; Natrajan, R; Yuan, Y; Schiavon, G; Turner, N; Sottoriva, A
    • The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer. 

      Barry, P; Vatsiou, A; Spiteri, I; Nichol, D; Cresswell, GD; Acar, A; Trahearn, N; Hrebien, S; Garcia-Murillas, I; Chkhaidze, K; Ermini, L; Huntingford, IS; Cottom, H; Zabaglo, L; Koelble, K; Khalique, S; Rusby, JE; Muscara, F; Dowsett, M; Maley, CC; Natrajan, R; Yuan, Y; Schiavon, G; Turner, N; Sottoriva, A (2018-10-01)
      Purpose: The most significant prognostic factor in early breast cancer is lymph node involvement. This stage between localized and systemic disease is key to understanding breast cancer progression; however, our knowledge ...
    • Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures. 

      Morrison, E; Wai, P; Leonidou, A; Bland, P; Khalique, S; Farnie, G; Daley, F; Peck, B; Natrajan, R (2016-12-26)
      The identification of functional driver events in cancer is central to furthering our understanding of cancer biology and indispensable for the discovery of the next generation of novel drug targets. It is becoming apparent ...